至 2028 年亚太地区胰岛素市场预测 - COVID-19 影响和区域分析 - 按类型（长效胰岛素、速效胰岛素、短效胰岛素和传统人胰岛素、浓缩胰岛素和复方胰岛素、生物仿制药胰岛素、胰高血糖素）类肽 1 (GLP-1)、笔和针以及其他）
No. of Pages: 205 | Report Code: BMIRE00027242 | Category: Life Sciences
No. of Pages: 205 | Report Code: BMIRE00027242 | Category: Life Sciences
先进移植的人工胰腺再生将成为显着的治疗趋势
身体细胞自然产生小分子、激素和蛋白质以保持身体机能正常。人工胰腺可以比标准治疗更好地控制 1 型糖尿病患者的血糖水平。对于 1 型糖尿病患者，连续血糖监测 (CGM) 设备可提供全天候的血糖水平信息，用于确定胰岛素的需求/剂量。胰岛素泵允许全天皮下注射胰岛素剂量。尽管经常监测血糖水平并调整剂量，但胰岛素注射并不能理想地重现胰腺释放的胰岛素的自然波。这使得患者不断努力避免长期高血糖或低血糖，这可能导致失明、糖尿病昏迷或危及生命的胰岛素休克。各个研究小组一直致力于胰腺细胞再生技术的研究。预计这些技术将在未来几年解决与糖尿病相关的疾病。
市场概述
亚太地区 (APAC) 是增长最快的胰岛素市场。亚太地区的市场细分为中国、印度、日本、韩国、澳大利亚和亚太地区其他地区。糖尿病患病率的不断上升以及肥胖等与生活方式相关的疾病发病率的上升推动了该地区的市场增长。一些市场参与者正将重点放在亚太地区国家，以实现地域扩张和其他战略。因此，该地区对于胰岛素市场参与者来说拥有巨大的潜力。过去十年，中国对胰岛素的需求不断增加。据 PharmExec 称，中国约有 1.144 亿糖尿病患者。预计到2022年，该国的糖尿病市场将达到66.7亿美元。虽然还有DPP-4抑制剂和GLP-1激动剂等其他药物，但胰岛素仍然是该国最常用的抗糖尿病药物。胰岛素治疗是 1 型糖尿病患者的主要治疗方法，因为胰腺会停止合成调节人体血糖水平的激素。当其他药物无法将血糖水平保持在所需范围内时，一些 2 型糖尿病或妊娠糖尿病患者需要服用胰岛素。据Statista统计，2018年中国人胰岛素及其类似物的市场规模约为29.6亿美元，预计到2030年将以每年4.4%的速度增长。
< p>
亚太地区胰岛素市场细分
< /p>
亚太地区胰岛素市场按类型和国家/地区进行细分。根据类型，市场分为长效胰岛素、速效胰岛素、短效胰岛素和短效胰岛素。传统人胰岛素、浓缩胰岛素和胰岛素组合胰岛素、生物仿制药胰岛素、胰高血糖素样肽-1 (GLP-1)、pen &针等。长效胰岛素细分市场在 2022 年占据最大市场份额。
Adocia；比奥康；礼来公司；葛兰素史克公司；默克公司有限公司；诺和诺德公司；辉瑞公司；赛诺菲；通化东宝药业有限公司；和 Wockhardt 是该地区胰岛素市场的领先公司。
Strategic insights for Asia-Pacific Insulin involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 7,288.17 Million |
| Market Size by 2028 | US$ 14,936.00 Million |
| Global CAGR (2022 - 2028) | 12.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia-Pacific Insulin refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia-Pacific Insulin Market is valued at US$ 7,288.17 Million in 2022, it is projected to reach US$ 14,936.00 Million by 2028.
As per our report Asia-Pacific Insulin Market, the market size is valued at US$ 7,288.17 Million in 2022, projecting it to reach US$ 14,936.00 Million by 2028. This translates to a CAGR of approximately 12.7% during the forecast period.
The Asia-Pacific Insulin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Insulin Market report:
The Asia-Pacific Insulin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific Insulin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific Insulin Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia-Pacific Insulin Market
